2023
Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderDisease-modifying therapiesMultiple sclerosisAnti-CD20 monoclonal antibody therapyCD20 IgG1 monoclonal antibodyInfant development outcomesPatient questionnaire responsesRelative infant doseOptica spectrum disorderMonoclonal antibody therapyIgG1 monoclonal antibodyMature breastmilkClinical relapseDisease activityInfant doseMAb therapyInfant outcomesAntibody therapyPostpartum womenPostpartum periodMedical recordsInfant growthPostpartum treatmentNeurological conditionsBreastmilk
2021
Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure
Yu AW, Pecsok M, Longbrake EE, Wesley SF. Neuroinflammation Associated With Tumor Necrosis Factor-α Inhibitor Exposure. Neurology Clinical Practice 2021, 11: e488-e496. PMID: 34484946, PMCID: PMC8382406, DOI: 10.1212/cpj.0000000000001014.Peer-Reviewed Original ResearchMRI findingsBrain MRIYale New Haven Health SystemNonspecific MRI findingsRetrospective cohort studyCommon abnormal findingDetailed chart reviewRisk stratification parametersElectronic medical recordsAdditional immunotherapyNeuroinflammatory phenomenaTNFi discontinuationTNFi exposureChart reviewCohort studyAbnormal findingsPeriod prevalenceT2 hyperintensityAutoimmune diseasesClinical spectrumInhibitor exposureMedical recordsTumor necrosisTNFiNeuroinflammation